New treatment for advanced liver cancer using light-activated nanoparticles
Clinical Translation of Interstitial Chemophototherapy with Light-Activated Nanoparticulate Doxorubicin
['FUNDING_OTHER'] · POP BIOTECHNOLOGIES, INC · NIH-10830696
This study is testing a new treatment for people with advanced liver cancer that combines a special chemotherapy drug with laser light to help target the tumor more effectively and reduce side effects.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | POP BIOTECHNOLOGIES, INC (nih funded) |
| Locations | 1 site (BUFFALO, UNITED STATES) |
| Trial ID | NIH-10830696 on ClinicalTrials.gov |
What this research studies
This research investigates a novel therapy called interstitial chemo-phototherapy (I-CPT) for patients with locally advanced liver cancers. It utilizes a special formulation of doxorubicin, a chemotherapy drug, which is encapsulated in nanoparticles that can be activated by laser light. When the nanoparticles are exposed to a specific wavelength of light, they release the drug directly into the tumor, potentially leading to more effective treatment with fewer side effects. The research aims to optimize this treatment approach and gather necessary safety data to prepare for human clinical trials.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with locally advanced liver cancer who have not responded to standard treatments.
Not a fit: Patients with early-stage liver cancer or those who do not have liver cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a more effective and targeted treatment option for patients with advanced liver cancer.
How similar studies have performed: Previous studies have shown promise in using light-activated therapies for cancer treatment, indicating potential success for this novel approach.
Where this research is happening
BUFFALO, UNITED STATES
- POP BIOTECHNOLOGIES, INC — BUFFALO, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: KUTSCHER, HILLIARD — POP BIOTECHNOLOGIES, INC
- Study coordinator: KUTSCHER, HILLIARD
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.